The Immunological Therapeutic Strategies for Controlling Multiple Sclerosis: Considerations during the COVID-19 Pandemic

A growing body of evidence initially suggested that patients with multiple sclerosis (MS) might be more susceptible to coronavirus disease 2019 (COVID-19). Moreover, it was speculated that patients with MS treated with immunosuppressive drugs might be at risk to develop a severe diseases course afte...

Descripción completa

Detalles Bibliográficos
Autores principales: Azimzadeh, Maryam, Möhn, Nora, Ghane Ezabadi, Sajjad, Moghimi Esfandabadi, Zahra, Soleimani, Alireza, Ranjbar, Elaheh, Jahromi, Maliheh, Seyedebrahimi, Reihaneh, Skripuletz, Thomas, Moharrami Kasmaie, Farshad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8470206/
https://www.ncbi.nlm.nih.gov/pubmed/34572585
http://dx.doi.org/10.3390/biom11091372
Descripción
Sumario:A growing body of evidence initially suggested that patients with multiple sclerosis (MS) might be more susceptible to coronavirus disease 2019 (COVID-19). Moreover, it was speculated that patients with MS treated with immunosuppressive drugs might be at risk to develop a severe diseases course after infection with the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV2). However, the recently published data have shown that MS patients do not have a higher risk for severe COVID-19. Although there is no indication that patients with MS and immunomodulatory/immunosuppressive therapy are generally at a higher risk of severe COVID-19, it is currently being emphasized that the hazards of poorly treated MS may outweigh the putative COVID-19 dangers. In this review, we discuss the challenges and considerations for MS patients in the COVID-19 pandemic.

Ejemplares similares